Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection

Journal of Viral Hepatitis

Volumn 13, Issue 8, 2006, Pages 544-551

  Feliu, A ^a   Carrion J A ^a   Massaguer, A ^a   Martinez Bauer E ^a   Garcia Retortillo M ^a   Gonzalez P ^a   Costa, J ^a   Sanchez Tapias J M ^a   Forns, X ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Early virological response; Hypervariable region 1; Interferon; Interferon sensitivity determining region; Viral load

Indexed keywords

EPOPEN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; VIRUS PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; SEQUENCE ALIGNMENT; VIRAL LOAD;

EID: 33746267138     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00714.x     Document Type: Article

References (34)

1. Garcia-Retortillo M, Forns X, Feliu A et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687.
2. Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-684.
3. Garcia-Retortillo M, Forns X, Llovet JM et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40: 699-707.
4. Prieto M, Berenguer M, Rayon JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-256.
5. Crippin JS, Mccashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-355.
6. Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003; 9: S90-S94.
7. Forns X, Garcia-Retortillo M, Serrano T et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396.
8. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-915.
9. Garcia-Retortillo M, Forns X. Prevention and treatment of hepatitis C virus recurrence after liver transplantation. J Hepatol 2004; 41: 2-10.
10. Samuel D, Bizollon T, Feray C et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642-650.
11. Farci P, Shimoda A, Coiana A et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-344.
12. Enomoto N, Sakuma I, Asahina Y et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-230.
13. Chalasani N, Manzarbeitia C, Ferenci P et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-298.
14. Morard I, Negro F. How should we treat recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42: 462-468.
15. Feliu A, Gay E, Garcia-Retortillo M, Saiz JC, Forns X. Evolution of hepatitis C virus quasispecies immediately following liver transplantation. Liver Transpl 2004; 10: 1131-1139.
16. Gretch DR, Polyak SJ, Wilson JJ, Carithers RL, Jr, Perkins JD, Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 1996; 70: 7622-7631.
17. Lyra AC, Fan X, Lang DM et al. Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology 2002; 123: 1485-1493.
18. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-264.
19. Weston SJ, Leistikow RL, Reddy KR et al. Reconstitution of hepatitis C virus-specific T-cell-mediated immunity after liver transplantation. Hepatology 2005; 41: 72-81.
20. Scheuer PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995; 22: 112-114.
21. Puig-Basagoiti F, Saiz JC, Forns X et al. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. J Med Virol 2001; 65: 35-44.
22. Fried MW, Shiffman M, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
23. Hadziyannis SJ, Sette H, Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
24. Manns MP, Mchutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
25. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
26. Hughes MG, Jr, Rudy CK, Chong TW et al. E2 quasispecies specificity of hepatitis C virus association with allografts immediately after liver transplantation. Liver Transpl 2004; 10: 208-216.
27. Sugimoto Y, Kuzushita N, Takehara T et al. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J Viral Hepat 2002; 9: 377-384.
28. Suzuki F, Arase Y, Suzuki Y et al. Single nucleotide polymorphism of the Mxa gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 2004; 11: 271-276.
29. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004; 53: 15-18.
30. Gale M, Jr, Blakely CM, Kwieciszewski B et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18: 5208-5218.
31. Bruguera M, Saiz JC, Franco S et al. Outbreak of nosocomial hepatitis C virus infection resolved by genetic analysis of HCV RNA. J Clin Microbiol 2002; 40: 4363-4366.
32. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (Genotype 1b) single-source outbreak in Germany: a 20-Year multicenter study. Hepatology 2000; 32: 91-96.
33. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107.
34. Neumann AU, Buti M, Lurie Y, Valdes A, Esteban R. The second phase HCV decline slope is the best predictor of sustained viral response during treatment of chronic HCV genotype 1 patients with peg-interferon-A-2B and ribavirin. Hepatology 2002; 36: 357A.